Efficacy of intranasal fentanyl spray versus other opioids for breakthrough pain in cancer

References

• Zeppetella G. Dynamics of breakthrough pain vs. pharmacokinetics of oral morphine: implications for management. Eur J Cancer Care (Engl) 2009;18:331-7
   PubMed Web of Science ®Google Scholar
• Bennett D, Burton AW, Fishman S, et al. Consensus panel recommendations for the assessment and management of breakthrough pain. Part 2 management. Pharm Ther 2005;6:354-61
   Google Scholar
• Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence and characteristics. Pain 1990;3:273-81
   Google Scholar
• Caraceni A, Martini C, Zecca E, et al. Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 2004;3:177-83
   Web of Science ®Google Scholar
• Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 1999;1-2:129-34
   Web of Science ®Google Scholar
• Zeppetella G, Ribeiro MDC. Opioids for the management of breakthrough episodic pain in cancer patients. Cochrane database of systematic reviews (Online) 2006;1:CD004311
   Google Scholar
• Fortner BV, Okon TA, Portenoy RK. A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 2002;1:38-44
   Web of Science ®Google Scholar
• Mercadante S, Radbruch L, Caraceni A, et al. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 2002;3:832-9
   Web of Science ®Google Scholar
• Summary of Product Characteristics Actiq. Cephalon UK Limited, Hertfordshire. Available at: http://emc.medicines.org.uk/medicine/11145/SPC/Actiq/ [Last accessed 8 December 2009]
   Google Scholar
• Sweeney MP, Bagg J, Baxter WP, et al. Oral disease in terminally ill cancer patients with xerostomia. Oral Oncol 1998;2:123-6
   Web of Science ®Google Scholar
• Chaushu G, Bercovici M, Dori S, et al. Salivary flow and its relation with oral symptoms in terminally ill patients. Cancer 2000;5:984-7
   Google Scholar
• Moksnes K, Fredheim OM, Klepstad P, et al. Early pharmacokinetics of nasal fentanyl: is there a significant arterio-venous difference?. Eur J Clin Pharmacol 2008;5:497-502
   Web of Science ®Google Scholar
• Dale O, Hjortkjaer R, Kharasch ED. Nasal administration of opioids for pain management in adults. Acta Anaesthesiol Scand 2002;7:759-70
   Web of Science ®Google Scholar
• Farrar JT, Cleary J, Rauck R, et al. Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Canc Inst 1998;8:611-16
   Google Scholar
• Slatkin N, Xie F, Messina J, et al. Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 2007;7:327-34
   Google Scholar
• Portenoy R, Taylor D, Messina J, et al. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 2006;9:805-11
   Web of Science ®Google Scholar
• Kress HG, Oronska A, Kaczmarek Z, et al. Efficacy and tolerability of intranasal fentanyl spray 50 to 200 microgram for breakthrough pain in patients with cancer: a phase III, multinational, randomized, double-blind, placebo-controlled, crossover trial with a 10-month, open-label extension treatment period. Clin Therapeut 2009;6:1177-91
   Web of Science ®Google Scholar
• Coluzzi PH, Schwartzberg L, Conroy JD, et al. Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate OTFC and morphine sulfate immediate release MSIR. Pain 2001;1-2:123-30
   Web of Science ®Google Scholar
• Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005;7521:897-900
   Web of Science ®Google Scholar
• Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004;20:3105-24
   Web of Science ®Google Scholar
• Jansen JP, Crawford B, Bergman G, et al. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. Value Health 2008;11:956-64
   PubMed Web of Science ®Google Scholar
• Farrar JT, Portenoy RK, Berlin JA, et al. Defining the clinically important difference in pain outcome measures. Pain 2000;3:287-94
   Web of Science ®Google Scholar
• Farrar JT, Berlin JA, Strom BL. Clinically important changes in acute pain outcome measures: a validation study. J Pain Symptom Manag 2003;5:406-11
   Web of Science ®Google Scholar
• Fryback DG, Stout NK, Rosenberg MA. An elementary introduction to Bayesian computing using WinBUGS. Int J Technol Assess Health Care. 2001;1:98-113
   Web of Science ®Google Scholar
• Edwards SJ, Clarke MJ, Wordsworth S, et al. Carbapenems versus other beta-lactams in the treatment of hospitalised patients with infection: a mixed treatment comparison. Curr Med Res Opin 2009;1:251-61
   Web of Science ®Google Scholar
• Goodman SN. Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med 1999;12:995-1004
   Web of Science ®Google Scholar
• Darwish M, Kirby M, Robertson P, et al. Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. Clinical drug investigation 2007;9:605-11
   Web of Science ®Google Scholar
• Fitzgibbon D, Morgan D, Dockter D, et al. Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. Pain 2003;3:309-15
   Web of Science ®Google Scholar
• Lennernas B, Hedner T, Holmberg M, et al. Pharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident pain. Br J Clin Pharmacol 2005;2:249-53
   Web of Science ®Google Scholar
• Mercadante S, Villari P, Ferrera P, et al. Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain. Br J Canc 2007;12:1828-33
   Web of Science ®Google Scholar
• Hagen N, Fisher K, Victorino C, et al. A titration strategy is needed to manage breakthrough cancer pain effectively: observations from data pooled from three clinical trials. J Palliat Med 2007;1:47-55
   Web of Science ®Google Scholar
• Blick SK, Wagstaff AJ. Fentanyl buccal tablet: in breakthrough pain in opioid-tolerant patients with cancer. Drugs 2006;18:2387-93
   Web of Science ®Google Scholar
• Pavis H, Wilcock A, Edgecombe J, et al. Pilot study of nasal morphine-chitosan for the relief of breakthrough pain in patients with cancer. J Pain Symptom Manag 2002;6:598-602
   Web of Science ®Google Scholar
• Zeppetella G. Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. Palliat Med 2001;4:323-8
   Web of Science ®Google Scholar
• Christie JM, Simmonds M, Patt R, et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998;10:3238-45
   Web of Science ®Google Scholar
• Portenoy RK, Payne R, Coluzzi P, et al. Oral transmucosal fentanyl citrate OTFC for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 1999;2-3:303-12
   Web of Science ®Google Scholar
• Mercadante S, Radbruch L, Davies AN, et al. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain – an open-label, randomised, crossover trial. Curr Med Res Opin 2009;25:2805-15
   PubMed Web of Science ®Google Scholar
• Fortner BV, Demarco G, Irving G, et al. Description and predictors of direct and indirect costs of pain reported by cancer patients. J Pain Symptom Manag 2003;1:9-18
   Web of Science ®Google Scholar
• Summary of Product Characteristics Effentora. Cephalon UK Limited, Hertfordshire. Available at: http://emc.medicines.org.uk/printfriendlydocument.aspx?documentid=21401&companyid=2290 [Last accessed 2 February 2010]
   Google Scholar
• Summary of Product Characteristics Instanyl. Nycomed UK Ltd, Buckinghamshire. Available at: http://emc.medicines.org.uk/printfriendlydocument.aspx?documentid=22242&companyid=1023 [Last accessed 2 February 2010]
   Google Scholar